Influence of adjuvant chemotherapy for operable breast cancer on results of treatment at relapse.
The influence of adjuvant chemotherapy (ACT) for operable breast cancer on the results of systemic therapy at relapse was retrospectively studied in 62 patients with recurrent disease. 32 had been treated with ACT [ACT (+) group] and the others had not [ACT (-) group]. The response rate (CR + PR) to the first treatment was 22% in the ACT (+) group and 43% in ACT (-) group. It is suggested that relapsing patients with a history of ACT respond poorly to the treatment as compared to those not receiving it.